PMID- 21114824
OWN - NLM
STAT- MEDLINE
DCOM- 20110322
LR  - 20240322
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 10
DP  - 2010 Nov 29
TI  - Prevalence of lipid abnormalities before and after introduction of lipid 
      modifying therapy among Swedish patients with dyslipidemia (PRIMULA).
PG  - 737
LID - 10.1186/1471-2458-10-737 [doi]
AB  - BACKGROUND: Data on the prevalence of dyslipidemia and attainment of goal/normal 
      lipid levels in a Swedish population are scarce. The objective of this study is 
      to estimate the prevalence of dyslipidemia and attainment of goal/normal lipid 
      levels in patients treated with lipid modifying therapy (LMT). METHODS: This 
      longitudinal retrospective observational study covers time periods before and 
      after treatment. Data were collected from 1994-2007 electronic patient records in 
      public primary healthcare centers in Uppsala County, Sweden. Patients were 
      included if they had been treated with LMT and had at least one lipid abnormality 
      indicating dyslipidemia and if complete lipid profile data were available. 
      Thresholds levels for lipids were defined as per Swedish guidelines. RESULTS: 
      Among 5,424 patients included, at baseline, the prevalence of dyslipidemia (>/=1 
      lipid abnormality) was by definition 100%, while this figure was 82% at 
      follow-up. At baseline, 60% had elevated low-density lipoprotein (LDL-C) combined 
      with low high-density lipoprotein (HDL-C) and/or elevated triglycerides (TG s), 
      corresponding figure at follow-up was 36%. Low HDL-C and/or elevated TGs at 
      follow-up remained at 69% for patients with type 2 diabetes mellitus (T2DM), 50% 
      among patients with coronary heart disease (CHD) and 66% among patients with 10 
      year CHD risk >20%. Of the total sample, 40% attained goal levels of LDL-C and 
      18% attained goal/normal levels on all three lipid parameters. CONCLUSIONS: 
      Focusing therapy on LDL-C reduction allows 40% of patients to achieve LDL-C goal 
      and helps reducing triglyceride levels. Almost 60% of patients experience 
      persistent HDL-C and/or triglyceride abnormality independently of LDL-C levels 
      and could be candidates for additional treatments.
FAU - Pettersson, Billie
AU  - Pettersson B
AD  - Center for Medical Technology Assessment, Linkoping University, Linkoping, 
      Sweden. billie_pettersson@merck.com
FAU - Ambegaonkar, Baishali
AU  - Ambegaonkar B
FAU - Sazonov, Vasilisa
AU  - Sazonov V
FAU - Martinell, Mats
AU  - Martinell M
FAU - Stalhammar, Jan
AU  - Stalhammar J
FAU - Wandell, Per
AU  - Wandell P
LA  - eng
PT  - Journal Article
DEP - 20101129
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Cholesterol, LDL)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticholesteremic Agents/therapeutic use
MH  - Cholesterol, LDL/blood/drug effects
MH  - Dyslipidemias/*drug therapy/*epidemiology/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Sweden/epidemiology
MH  - Treatment Outcome
PMC - PMC3009647
EDAT- 2010/12/01 06:00
MHDA- 2011/03/23 06:00
PMCR- 2010/11/29
CRDT- 2010/12/01 06:00
PHST- 2010/06/08 00:00 [received]
PHST- 2010/11/29 00:00 [accepted]
PHST- 2010/12/01 06:00 [entrez]
PHST- 2010/12/01 06:00 [pubmed]
PHST- 2011/03/23 06:00 [medline]
PHST- 2010/11/29 00:00 [pmc-release]
AID - 1471-2458-10-737 [pii]
AID - 10.1186/1471-2458-10-737 [doi]
PST - epublish
SO  - BMC Public Health. 2010 Nov 29;10:737. doi: 10.1186/1471-2458-10-737.